Sign Out
Metastatic Breast Cancer: Perjeta is indicated in combination with Herceptin and docetaxel for patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.
Early Breast Cancer: Perjeta is indicated in combination with Herceptin and chemotherapy for the: neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either >2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer (see Dosage & Administration and Pharmacology: Pharmacodynamics: Clinical/Efficacy Studies under Actions); adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (see Pharmacology: Pharmacodynamics: Clinical/Efficacy Studies under Actions).
